Investigation of the Effects of Pharmaceutical Care Provided by a Clinical Pharmacist on Stroke Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Stroke
- Sponsor
- Marmara University
- Enrollment
- 260
- Locations
- 1
- Primary Endpoint
- Blood pressure
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
To evaluate the effects of the 1-year pharmaceutical care program offered by the clinical pharmacist to the patients admitted to the neurology service with the diagnosis of stroke, on medication adherence, quality of life, and clinical outcomes of the patients.
Detailed Description
The study was conducted as a parallel randomized controlled study in the Neurology Clinic of a University Hospital in Turkey. Patients were randomly assigned to intervention and usual care groups. While the patients in the usual care group are given routine health services by the neurologist during their hospitalization and for 1 year after discharge; In addition to these routine services, the intervention group was provided with pharmaceutical care by a clinical pharmacist during the same period. The study was always conducted by the same neurologist and clinical pharmacist. Patient medication adherence, quality of life, and clinical parameters were evaluated at the beginning of the study and at the 12th month.
Investigators
Mesut Sancar
Prof. Dr.
Marmara University
Eligibility Criteria
Inclusion Criteria
- •being diagnosed with stroke,
- •being 18 years old or older,
- •being in the cognition to receive the training to be given
Exclusion Criteria
- •Not having adequate cognitive function such as dementia,
- •being pregnant, lactating,
- •having cancer.
Outcomes
Primary Outcomes
Blood pressure
Time Frame: 1, 3, 6, 9 and 12 months
Blood pressure was checked and recorded by a qualified nurse during the hospital stay and at control visits. Measurements were recorded as mmHg.
Medication Adherence
Time Frame: 3, 6, 9 and 12 months
Adherence to Stroke Prevention Medications (Anti platelets, Anticoagulants, Statins, antihypertensives, antidiabetics) measured by Morisky-Green-Levine Adherence Scale (1-4) where higher scores indicate higher levels of reported adherence.
HbA1c
Time Frame: 1, 3, 6, 9 and 12 months
HbA1c (glycated hemoglobin) value was collected from medical records and recorded as a percentage.
LDL cholesterol
Time Frame: 1, 3, 6, 9 and 12 months
Low density lipoprotein-cholesterol level was collected from medical records and recorded as mg/dL
Triglyceride
Time Frame: 1, 3, 6, 9 and 12 months
Triglyceride level was collected from medical records and recorded as mg/dL.
Body mass index
Time Frame: 1, 3, 6, 9 and 12 months
Body mass index (BMI) was collected from medical records and recorded as kg/m2
Secondary Outcomes
- Drug Related Problem(1 year)
- The National Institutes of Health Stroke Scale(24 hours before discharge, 3, 6, 9 and 12 months)
- Measuring Quality of Life(3, 6 and 12 months)
- Stroke Recurrence(1 year)